Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with chemotherapy as second-line treatment for non-small cell lung cancer
ChiCTR2000033148Phase 4Recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Wuxi People's Hospital. Primary endpoint: Progression-free survival. Started Jan 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000033148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033148.